These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18719095)

  • 1. An engineered selenocysteine defines a unique class of antibody derivatives.
    Hofer T; Thomas JD; Burke TR; Rader C
    Proc Natl Acad Sci U S A; 2008 Aug; 105(34):12451-6. PubMed ID: 18719095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the UGA-recoding and SECIS-binding activities of SECIS-binding protein 2.
    Bubenik JL; Miniard AC; Driscoll DM
    RNA Biol; 2014; 11(11):1402-13. PubMed ID: 25692238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly defined antibody conjugation through a selenocysteine interface.
    Hofer T; Skeffington LR; Chapman CM; Rader C
    Biochemistry; 2009 Dec; 48(50):12047-57. PubMed ID: 19894757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural characterization of a human Fc fragment engineered for extended serum half-life.
    Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
    Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-Specific Incorporation of Selenocysteine by Genetic Encoding as a Photocaged Unnatural Amino Acid.
    Welegedara AP; Adams LA; Huber T; Graham B; Otting G
    Bioconjug Chem; 2018 Jul; 29(7):2257-2264. PubMed ID: 29874064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B Cell-Based Seamless Engineering of Antibody Fc Domains.
    Hashimoto K; Kurosawa K; Murayama A; Seo H; Ohta K
    PLoS One; 2016; 11(12):e0167232. PubMed ID: 27907066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selenocysteine insertion or termination: factors affecting UGA codon fate and complementary anticodon:codon mutations.
    Berry MJ; Harney JW; Ohama T; Hatfield DL
    Nucleic Acids Res; 1994 Sep; 22(18):3753-9. PubMed ID: 7937088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review.
    Fonseca MHG; Furtado GP; Bezerra MRL; Pontes LQ; Fernandes CFC
    Int J Biol Macromol; 2018 Nov; 119():306-311. PubMed ID: 30041038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of gene expression by stop codon recoding: selenocysteine.
    Copeland PR
    Gene; 2003 Jul; 312():17-25. PubMed ID: 12909337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribosomal protein L30 is a component of the UGA-selenocysteine recoding machinery in eukaryotes.
    Chavatte L; Brown BA; Driscoll DM
    Nat Struct Mol Biol; 2005 May; 12(5):408-16. PubMed ID: 15821744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative methods for developing Fc mutants with extended half-lives.
    Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
    Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
    Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
    Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGA codon position affects the efficiency of selenocysteine incorporation into glutathione peroxidase-1.
    Wen W; Weiss SL; Sunde RA
    J Biol Chem; 1998 Oct; 273(43):28533-41. PubMed ID: 9774484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function.
    Kelley RF; Meng YG
    Methods Mol Biol; 2012; 901():277-93. PubMed ID: 22723108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
    Dall'Acqua WF; Kiener PA; Wu H
    J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowing when not to stop: selenocysteine incorporation in eukaryotes.
    Low SC; Berry MJ
    Trends Biochem Sci; 1996 Jun; 21(6):203-8. PubMed ID: 8744353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.